#1 Clinical Trials Search in Europe

Povetacicept

Povetacicept, also known as ALPN-303, is an investigational drug currently being studied in clinical trials for various autoimmune diseases. These trials aim to evaluate the safety, efficacy, and potential benefits of Povetacicept in treating conditions such as autoimmune kidney diseases, autoimmune cytopenias, and specifically, Immunoglobulin A Nephropathy (IgAN). The drug is administered through subcutaneous injections, typically every 4 weeks, and researchers are exploring its effects on reducing symptoms and preserving organ function in affected patients.

Table of Contents

Introduction

Povetacicept, also known as ALPN-303, is an innovative medication currently being studied for the treatment of various autoimmune diseases[1][2][3]. This article aims to provide patients with a comprehensive overview of Povetacicept, including its potential uses, how it works, and the ongoing clinical trials investigating its effectiveness and safety.

What is Povetacicept?

Povetacicept is a novel drug designed to target specific components of the immune system involved in autoimmune diseases. It is being developed as a potential treatment for several conditions where the body’s immune system mistakenly attacks healthy tissues[1][2].

Conditions Treated by Povetacicept

Based on the ongoing clinical trials, Povetacicept is being investigated for the treatment of several autoimmune diseases, including:

  • Kidney-related autoimmune diseases[1]:
    • Immunoglobulin A (IgA) nephropathy: A kidney disease caused by deposits of IgA antibodies in the kidneys
    • Membranous nephropathy: A kidney disease characterized by thickening of the glomerular basement membrane
    • Lupus nephritis: Kidney inflammation caused by systemic lupus erythematosus
    • Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis: A group of diseases causing inflammation of blood vessels
  • Autoimmune cytopenias[2]:
    • Immune thrombocytopenia (ITP): A blood disorder causing a decrease in platelets
    • Autoimmune hemolytic anemia: A condition where the immune system destroys red blood cells
    • Cold agglutinin disease: A rare type of autoimmune hemolytic anemia

How Povetacicept Works

While the exact mechanism of action is not detailed in the provided information, Povetacicept is likely designed to modulate the immune system’s response in autoimmune diseases. It may work by targeting specific immune cells or signaling pathways involved in the autoimmune process, potentially reducing inflammation and tissue damage[1][2].

How Povetacicept is Administered

Povetacicept is administered as a subcutaneous injection (an injection under the skin) every 4 weeks[1][2]. This method of administration allows for convenient dosing and potentially better patient compliance compared to more frequent dosing regimens.

Current Clinical Trials

Several clinical trials are currently underway to evaluate the safety, efficacy, and optimal dosing of Povetacicept:

  • RUBY-3 trial[1]: An open-label study investigating multiple dose levels of Povetacicept in adults with autoimmune kidney diseases. The trial includes a 6-month treatment period with possible extensions.
  • RUBY-4 trial[2]: An open-label study evaluating Povetacicept in adults with autoimmune cytopenias. This trial also includes a 6-month treatment period with a possible extension.
  • RAINIER trial[3]: A Phase 3, randomized, double-blind, placebo-controlled study specifically focused on adults with Immunoglobulin A Nephropathy (IgAN). This trial aims to assess the efficacy of Povetacicept in reducing proteinuria and preserving renal function.

Potential Benefits

The ongoing clinical trials are designed to evaluate several potential benefits of Povetacicept, including:

  • Reduction in proteinuria (excess protein in urine) in kidney diseases[3]
  • Preservation of kidney function[3]
  • Improvement in blood cell counts in autoimmune cytopenias[2]
  • Overall improvement in disease activity and quality of life for patients with autoimmune diseases

Safety Considerations

As with any new medication, safety is a primary concern in the clinical trials of Povetacicept. The studies are closely monitoring for any adverse events (side effects) that may occur during treatment[1][2]. The type, incidence, severity, and seriousness of these events are being carefully evaluated to ensure the safety profile of the drug is well understood before it potentially becomes available for wider use.

Frequently Asked Questions

1. How long does it take for Povetacicept to start working?

The time it takes for Povetacicept to show effects may vary depending on the condition being treated and individual patient factors. The ongoing clinical trials are designed to evaluate the drug’s efficacy over several months, with some studies lasting up to 104 weeks (2 years)[3]. More specific information about the onset of action will likely be available as the trials progress.

2. Can Povetacicept cure autoimmune diseases?

While Povetacicept shows promise in treating various autoimmune diseases, it’s important to note that most autoimmune conditions are chronic and do not have a definitive cure. The goal of treatments like Povetacicept is to manage symptoms, reduce disease activity, and improve quality of life. The ongoing clinical trials aim to determine how effective Povetacicept is in achieving these goals.

3. Are there any known side effects of Povetacicept?

As Povetacicept is still in clinical trials, a comprehensive list of potential side effects is not yet available. The current studies are carefully monitoring for any adverse events to establish the safety profile of the drug[1][2]. Patients participating in clinical trials are closely monitored for any unexpected reactions or side effects.

Summary

Aspect Details
Drug Name Povetacicept (ALPN-303)
Administration Subcutaneous injection every 4 weeks
Conditions Studied Autoimmune kidney diseases, Autoimmune cytopenias
Current Stage Clinical trials (Phase 2 and 3)
Potential Benefits Reduction in proteinuria, Preservation of kidney function, Improvement in blood cell counts
Safety Under evaluation in ongoing clinical trials

Glossary

  • Autoimmune disease – A condition where the body’s immune system mistakenly attacks healthy cells
  • Subcutaneous injection – An injection given under the skin
  • Proteinuria – The presence of excess proteins in the urine, often a sign of kidney disease
  • Nephropathy – A general term for disease or damage of the kidney
  • Cytopenia – A condition where there is a lower-than-normal number of blood cells
  • Vasculitis – Inflammation of blood vessels
  • Glomerular filtration rate (GFR) – A measure of how well the kidneys are filtering waste from the blood

Trial sources

  • [1]: https://clinicaltrials.gov/study/NCT05732402
  • [2]: https://clinicaltrials.gov/study/NCT05757570
  • [3]: https://clinicaltrials.gov/study/NCT06564142
Aspect Details
Drug Name Povetacicept (ALPN-303)
Administration Subcutaneous injection every 4 weeks
Conditions Studied Immunoglobulin A Nephropathy, Membranous Nephropathy, ANCA-Associated Vasculitis, Immune Thrombocytopenia, Autoimmune Hemolytic Anemia, Cold Agglutinin Disease
Trial Phases Open-label studies and Phase 3 randomized controlled trial
Primary Outcomes Safety and tolerability, change in proteinuria, eGFR slope
Secondary Outcomes Change in eGFR, time to kidney disease progression, quality of life measures
Treatment Duration 6 months to 2 years, with possible extensions
Key Trial RAINIER study for IgA Nephropathy (Phase 3, placebo-controlled)

FAQ

  • What is Povetacicept and what conditions is it being studied for? Povetacicept, also known as ALPN-303, is an investigational drug being studied for various autoimmune diseases. It's currently in clinical trials for conditions such as Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Immune Thrombocytopenia, Autoimmune Hemolytic Anemia, and Cold Agglutinin Disease.
  • How is Povetacicept administered in these clinical trials? In the clinical trials, Povetacicept is administered through subcutaneous injections (injections under the skin) approximately every 4 weeks. The duration of treatment varies, but some trials involve a 6-month treatment period with possible extensions.
  • What are the main goals of these clinical trials? The main goals of these clinical trials are to evaluate the safety and potential benefits of Povetacicept in treating various autoimmune diseases. Researchers are assessing its efficacy in reducing disease symptoms, preserving organ function (especially in kidney-related conditions), and monitoring any side effects or adverse events.
  • What is being measured in these trials to determine if Povetacicept is effective? The trials are measuring various outcomes to determine Povetacicept's effectiveness. These include changes in protein levels in urine, kidney function (estimated glomerular filtration rate or eGFR), time to kidney disease progression, and quality of life measures such as fatigue scores. The trials also closely monitor the safety profile by tracking adverse events.
  • Are there any placebo-controlled studies for Povetacicept? Yes, there is a Phase 3, randomized, double-blind, placebo-controlled study (RAINIER) specifically for adults with Immunoglobulin A Nephropathy (IgAN). This study compares the efficacy of Povetacicept against a placebo in reducing proteinuria and preserving renal function.

Ongoing Clinical Trials on Povetacicept

  • Phase 2 Randomized Study of Povetacicept to Assess Safety and Effectiveness in Adults with Generalized Myasthenia Gravis

    Recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Poland

  • A Study of Povetacicept Compared to Tacrolimus for Adults with Primary Membranous Nephropathy

    Recruiting

    4 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Germany Hungary Ireland Italy The Netherlands +1

  • Study on Povetacicept for Patients with Autoimmune Cytopenias (wAIHA, CAD, ITP)

    Not recruiting

    2 1 1
    Investigated drugs:
    Austria Germany Italy Norway Spain

  • Study on the Effects of Povetacicept for Adults with IgA Nephropathy

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Croatia Czechia Denmark Estonia +13

Glossary

  • Povetacicept: An investigational drug, also known as ALPN-303, being studied for the treatment of various autoimmune diseases. It is administered through subcutaneous injections.
  • Immunoglobulin A Nephropathy (IgAN): A kidney disease caused by deposits of the protein immunoglobulin A (IgA) in the kidneys, which can lead to inflammation and kidney damage over time.
  • Membranous Nephropathy: A kidney disease characterized by thickening of the membrane in the glomeruli (filtering units) of the kidneys, which can lead to protein loss in the urine and kidney dysfunction.
  • Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis: A group of autoimmune disorders characterized by inflammation of small blood vessels, which can affect various organs, including the kidneys.
  • Immune Thrombocytopenia: A blood disorder where the immune system mistakenly attacks and destroys platelets, leading to a low platelet count and increased risk of bleeding.
  • Autoimmune Hemolytic Anemia: A condition where the immune system mistakenly attacks and destroys red blood cells, leading to anemia.
  • Cold Agglutinin Disease: A rare type of autoimmune hemolytic anemia where cold temperatures trigger the immune system to destroy red blood cells.
  • Subcutaneous Injection: A method of administering medication by injecting it into the layer of tissue just beneath the skin.
  • Proteinuria: The presence of excess proteins in the urine, which can be a sign of kidney damage or disease.
  • Estimated Glomerular Filtration Rate (eGFR): A measure of kidney function that estimates how well the kidneys are filtering waste from the blood.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Serious Adverse Event (SAE): An adverse event that results in death, is life-threatening, requires hospitalization, causes a significant incapacity, or requires intervention to prevent permanent impairment.
  • Placebo: A substance or treatment with no active therapeutic effect, used as a control in clinical trials to test the effectiveness of new drugs.
  • Double-blind Study: A type of clinical trial where neither the participants nor the researchers know who is receiving the actual treatment and who is receiving a placebo.